---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-034826"
form_type: "8-K"
ticker: "PDSB"
cik: "0001472091"
company_name: "PDS Biotechnology Corp"
filed_at: "2023-07-17T23:59:59+00:00"
generated_at: "2026-06-13T07:36:49.842413+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# PDS Biotechnology shareholders approve 2.4M share increase in equity plan, reelect directors

## Summary
- Stockholders approved Third Amended Restated 2014 Equity Plan, increasing authorized shares from 4,165,535 to 6,565,535.
- Elected Class B directors Kamil Ali-Jackson and Ilian Iliev; each received >5M votes for, 10M+ broker non-votes.
- Ratified KPMG as independent auditor for FY2023 with 17.2M votes for, 259K against.
- Non-binding advisory vote on executive compensation approved: 6.0M for, 1.4M against, 10.1M broker non-votes.

## SEC filing metadata
- accession: 0001140361-23-034826
- form_type: 8-K
- ticker: PDSB
- cik: 0001472091
- company_name: PDS Biotechnology Corp
- filed_at: 2023-07-17T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1472091/000114036123034826/0001140361-23-034826-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1472091/000114036123034826/brhc20055890_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-034826
- JSON: https://secwatch.observer/filing/0001140361-23-034826.json
- Plain text: https://secwatch.observer/filing/0001140361-23-034826.txt

## Key facts
- Shareholder Votes
  PDS Biotechnology Corp shareholders approved Approval, by non-binding advisory vote, of the compensation of the Company’s named executive officers.
  - Proposal: say on pay
  - Outcome: passed
  source text: The Company’s stockholders voted to approve, by non-binding advisory vote, the compensation of the Company’s named executive officers.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1472091/000114036123034826/0001140361-23-034826-index.htm
- Shareholder Votes
  PDS Biotechnology Corp shareholders approved Approval of the Third Amended and Restated PDS Biotechnology Corporation 2014 Equity Incentive Plan.
  - Proposal: equity plan
  - Outcome: passed
  source text: The Company’s stockholders voted to approve the Third Amended and Restated PDS Biotechnology Corporation 2014 Equity Incentive Plan.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1472091/000114036123034826/0001140361-23-034826-index.htm
- Shareholder Votes
  PDS Biotechnology Corp shareholders approved Ratification of Appointment of KPMG US LLP at the 2023-12-31 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-12-31
  source text: The Company’s stockholders ratified the appointment of KPMG US LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1472091/000114036123034826/0001140361-23-034826-index.htm
- Shareholder Votes
  PDS Biotechnology Corp shareholders approved Election of Class B Directors.
  - Proposal: director election
  - Outcome: passed
  source text: The Company’s stockholders elected the following directors to serve as Class B directors until the 2026 Annual Meeting of Stockholders of the Company or until their successors are duly elected and qualified.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1472091/000114036123034826/0001140361-23-034826-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.